Researchers at the University of London have recently discovered that six of marijuana’s many cannabinoids could potentially represent a less expensive, and more effective treatment for leukemia.
The October 2013 research published online at the National Center for Biotechnology Information (NCBI), emphasized new research performed by scientists at the Department of Oncology at St. George’s University of London. Where scientists studied six different cannabinoids and found each to have potent anticancer compounds – beneficial in disrupting leukemia cells.
Wai Liu, PhD and the lead author of the new research explained the results of the latest study in Monday’s press release
“These agents are able to interfere with the development of cancerous cells, stopping them in their tracks and preventing them from growing. In some cases, by using specific dosage patterns, they can destroy cancer cells on their own.”
Dr. Liu’s research primarily focused on cannabinoids that lacked psychoactive traits, including the CBD, CBG and CBGV cannabinoid.
Cannabinoids are the bioactive components of the Cannabis plant that display a diverse range of therapeutic qualities. We explored the activity of six cannabinoids, used both alone and in combination in leukaemic cells. Cannabinoids were cytostatic and caused a simultaneous arrest at all phases of the cell cycle. Re-culturing pre-treated cells in drug-free medium resulted in dramatic reductions in cell viability. Furthermore, combining cannabinoids was not antagonistic. We suggest that the activities of some cannabinoids are influenced by treatment schedules; therefore, it is important to carefully select the most appropriate strategy in order to maximise their efficacy.